Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood biopsy study aims to improve cancer detection and monitoring

NCT ID NCT05089747

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see if these blood tests can help doctors better understand cancer and make more informed treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 6,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Dec 2047

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult with solid cancer

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (\>18y) * Owing a social security insurance * Any solid cancer diagnosed by histopathology or cytology * Patient with blood sampling required as per standard of care * Informed consent signed Exclusion Criteria: * Refusal to participate * No blood sampling required as per standard of care * Hemoglobin \< 7g/dl (\< 9g/dl if respiratory or cardiovascular disease history) * Heterologous blood transfusion in the last 48 hours * Weight under 20 kg

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult with solid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult with solid cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Edouard Herriot / Groupement Hospitalier Centre

    RECRUITING

    Lyon, 69003, France

  • Hôpital Lyon-Sud / Groupement Hospitalier Sud

    RECRUITING

    Pierre-Bénite, 69495, France

  • Oncologie médicale Hôpital Lyon-Sud / Groupement Hospitalier Sud

    RECRUITING

    Pierre-Bénite, 69495, France

  • Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique Hôpital Lyon-Sud / Groupement Hospitalier Sud

    RECRUITING

    Pierre-Bénite, 69310, France

  • Service de Pneumologie Hôpital Croix-Rousse / Groupement Hospitalier Nord

    RECRUITING

    Lyon, 69004, France

  • Service de Pneumologie Hôpital Louis Pradel / Groupement Hospitalier Est

    RECRUITING

    Bron, 69500, France

  • Service de dermatologie Hôpital Lyon-Sud / Groupement Hospitalier Sud

    RECRUITING

    Pierre-Bénite, 69495, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.